Results 101 to 110 of about 122,669 (246)

Review: Treatment options for nonalcoholic fatty liver disease

Therapeutic Advances in Gastroenterology, 2008
Nonalcoholic fatty liver disease comprises a range of disorders from steatosis and steatohepatitis through to cirrhosis. Nonalcoholic steatohepatitis can progress to cirrhosis and liver-related death.
Shivakumar Chitturi
doaj   +1 more source

Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate MetabolismSummary

Cellular and Molecular Gastroenterology and Hepatology, 2019
A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes.
Kyle S. McCommis, Brian N. Finck
doaj   +1 more source

The function role of HIGD1A in nonalcoholic steatohepatitis from chronic hepatitis B

, 2023
Minran Li, Jinzhong Li, Dehua Wang, Tao‐yuan Li, Lihong Ye, Xujing Liang, Hai-cong Zhang, Zhiquan Liu, Xuedong Zhang, Junqing Li, Yunyan Liu, Calvin Q. Pan, Erhei Dai   +12 more
openalex   +1 more source

Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis

Hepatology, 2019
Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental factors and genetic determinants that cannot be completely replicated in animals. Notwithstanding, preclinical models are needed to understand NASH pathophysiology
Geoffrey C. Farrell, J. Schattenberg, Isabelle Leclercq, Matthew M. Yeh, Robert Goldin, Narci C. Teoh, Detlef Schuppan   +6 more
semanticscholar   +1 more source

Harnessing Gut Microbiome–Brain–Liver Crosstalk: Novel Therapeutic Strategies for Metabolic Dysfunction‐Associated Steatotic Liver Disease

Medicine Bulletin, EarlyView.
This review reveals the complex mechanisms by which the brain–gut–liver axis (particularly the gut microbiota and its metabolites) drives MASLD, highlighting the therapeutic value of using phages to target and eliminate pathogenic bacteria and their metabolic products.
Xingtao Zhao, Ruolan Li, Jingdong Zhao, Ruiqi Sun, Shuo Zhang, Qiong Pan, Hongyan Lu, Jin Chai   +7 more
wiley   +1 more source

Sudden Death Due to Association between NAFLD and Cardiovascular Changes in a 37-Year-Old Man: a Case Report

Acta Medica Iranica, 2016
Fatty liver disease (FLD) is the most prevalent form of liver disease worldwide. Overnutrition can induce nonalcoholic fatty liver disease (NAFLD), a spectrum of conditions ranging from simple steatosis [or nonalcoholic fatty liver (NAFL)] to ...
Maryam Ameri, Shahrokh Mehrpisheh, Azadeh Memarian, Payam Balvayeh   +3 more
doaj  

Esteatohepatite não alcoólica.

Acta Médica Portuguesa, 1995
The authors present a case of a nonalcoholic steatohepatitis, with progression to liver cirrhosis in an obese female patient. A review of the literature, possible evolution, and principle pathological processes involved is made.
P M da Silva, T Eliseu, M M Costa, H Bastos, F L Nobre   +4 more
doaj   +1 more source

Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial [PDF]

, 2017
Shahinul Alam, SKM Nazmul Hasan, Golam Mustafa, Mahabubul Alam, Mohammad Amjad Kamal, Nooruddin Ahmad   +5 more
openalex   +1 more source

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Gastroenterology, 2016
BACKGROUND & AIMS Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
V. Ratziu, S. Harrison, S. Francque, P. Bedossa, P. Lehert, L. Serfaty, M. Romero‐Gomez, J. Boursier, M. Abdelmalek, Steve Caldwell, J. Drenth, Q. Anstee, D. Hum, Rémy Hanf, A. Roudot, S. Megnien, B. Staels, A. Sanyal   +17 more
semanticscholar   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, EarlyView.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source